Wednesday, July 8, 2026

pharma · Severe, Refractory Systemic Lupus Erythematosus · Refractory Progressive Multiple Sclerosis · AUTL

Autolus

Autolus clinical programs — 16 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Munich, Bayern 81377, DE HQ
117 Employees
Public company Type
AUTL · NYSE Ticker
Company details
Status
Public
HQ
Munich, Bayern 81377, DE
Employees
117
Programs
16
Drugs
17
Patents
49
Intelligence · Clinical Programs

Autolus projects

16 ClinicalTrials.gov programs sponsored by Autolus.

Autolus has 16 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AUTO CAR T cell therapy

    Autolus GmbH

    Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy

    phase 2 mab active

    1 trial
  2. AUTO-LT1

    Autolus GmbH

    Potential malignancy in patients who received treatment with Autolus CAR T cell therapy.

    phase 2 small molecule active

    1 trial
  3. AUTO1

    Autolus GmbH

    Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

    phase 2 mab active

    2 trials
  4. AUTO1-SL2

    Autolus GmbH

    Systemic Lupus Erythematosus with Active Lupus Nephritis

    phase 2 small molecule active

    1 trial
  5. AUTO2

    Autolus GmbH

    Multiple Myeloma

    phase 2 mab terminated

    1 trial
  6. AUTO3

    Autolus GmbH

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 mab terminated

    1 trial
  7. AUTO3 (CD19/22 CAR T cells

    Autolus GmbH

    B Acute Lymphoblastic Leukemia

    phase 2 mab completed

    1 trial
  8. AUTO4

    Autolus GmbH

    T Cell Non-Hodgkin Lymphoma

    phase 2 mab terminated

    1 trial
  9. Genoxal polvo para solución inyectable y para...

    Autolus GmbH

    Relapsed or refractory B cell acute lymphoblastic leukaemia

    phase 2 small molecule active

    1 trial
  10. Obecabtagene Autoleucel

    Autolus GmbH

    Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial
  11. Obecabtagene autoleucel

    Autolus GmbH

    Acute Lymphocytic Leukemia (ALL)

    phase 2 small molecule active

    1 trial
  12. Obecabtagene autoleucel

    Autolus GmbH

    Lupus Nephritis

    phase 2 mab active

    1 trial
  13. AUTO1-MS1

    Autolus GmbH

    Refractory Progressive Multiple Sclerosis

    phase 1 other active

    1 trial
  14. AUTO1-SL1

    Autolus GmbH

    Severe, Refractory Systemic Lupus Erythematosus

    phase 1 other active

    1 trial
  15. Obecabtagene autoleucel (obe-cel)

    Autolus GmbH

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial
  16. Obecabtagene autoleucel (obe-cel)

    Autolus GmbH

    Progressive Multiple Sclerosis

    phase 1 mab active

    1 trial

Frequently asked questions

How many clinical projects does Autolus have?

16 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.